Biogen (BIIB): Mid-Stage Pipeline Overshadowing Tecfidera Launch - Goldman

January 29, 2014 2:43 PM

Goldman Sachs maintained a Neutral rating on Biogen (NASDAQ: BIIB) with a modified price target of $304.00 (from $283.00). Analyst ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found